LivaNova PLC (LIVN)
NASDAQ: LIVN · IEX Real-Time Price · USD
62.92
0.00 (0.00%)
At close: May 3, 2024, 4:00 PM
64.15
+1.23 (1.95%)
After-hours: May 3, 2024, 4:57 PM EDT
LivaNova Revenue
LivaNova had revenue of $1.19B in the twelve months ending March 31, 2024, with 13.40% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $294.91M with 11.96% year-over-year growth. In the year 2023, LivaNova had annual revenue of $1.15B with 12.89% growth.
Revenue (ttm)
$1.19B
Revenue Growth
+13.40%
P/S Ratio
2.92
Revenue / Employee
$408,634
Employees
2,900
Market Cap
3.46B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
Dec 31, 2018 | 1.11B | 94.68M | 9.35% |
Dec 31, 2017 | 1.01B | 47.42M | 4.91% |
Dec 31, 2016 | 964.86M | 673.30M | 230.93% |
Apr 24, 2015 | 291.56M | 9.54M | 3.38% |
Apr 25, 2014 | 282.01M | 27.69M | 10.89% |
Apr 26, 2013 | 254.32M | -426.21M | -62.63% |
Dec 31, 2012 | 680.53M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 5.86B |
Integer Holdings | 1.63B |
Prestige Consumer Healthcare | 1.13B |
HUTCHMED (China) | 838.00M |
iRhythm Technologies | 513.17M |
Ultragenyx Pharmaceutical | 434.25M |
Axonics | 387.14M |
Axsome Therapeutics | 270.60M |
LIVN News
- 4 days ago - LivaNova Reports First-Quarter 2024 Results - Business Wire
- 5 days ago - LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer - Business Wire
- 10 days ago - LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident - Business Wire
- 6 weeks ago - LivaNova to Announce First-Quarter 2024 Results - Business Wire
- 6 weeks ago - LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea - Business Wire
- 2 months ago - LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029 - Business Wire
- 2 months ago - LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes - Business Wire
- 2 months ago - LivaNova to Present at the Barclays Global Healthcare Conference - Business Wire